Veterinary Orthobiologics Market to Grow with a CAGR of 8.15% through 2029
Rising Incidence of
Musculoskeletal Disorders and Increasing Pet Ownership and Humanization of Pets are expected to
drive the Global Veterinary Orthobiologics Market growth in the forecast
period, 2025-2029
According to TechSci Research report, “Veterinary
Orthobiologics Market – Global Industry Size, Share, Trends, Competition
Forecast & Opportunities, 2029”, the Global Veterinary Orthobiologics
Market stood at USD 689.85 Million in 2023 and is anticipated to grow with a
CAGR of 8.15% in the forecast period through 2029.
The proliferation of veterinary clinics, especially
those specializing in orthopedics and regenerative medicine, is a major growth
driver. The increasing number of clinics offering orthobiologic treatments
enhances accessibility and meets the rising demand for these advanced
therapies. The establishment of specialized veterinary practices, which focus
on musculoskeletal conditions and regenerative medicine, further supports
market growth. These clinics, equipped with state-of-the-art technologies and
expert knowledge, promote the use of cutting-edge orthobiologic therapies, thus
broadening the scope of treatment options available. Also, the integration of
advanced training programs into veterinary education plays a crucial role in
driving market expansion. Veterinary schools and professional organizations are
increasingly offering specialized training and continuing education on orthobiologic
treatments. This education ensures that veterinarians are well-informed about
the latest advancements and techniques, facilitating the adoption of innovative
therapies and contributing to market growth.
Investments in research and development are also
pivotal in advancing the veterinary orthobiologics market. Increased funding
from pharmaceutical companies, biotechnology firms, and research institutions
drives innovation in orthobiologic products. These R&D efforts focus on
enhancing existing therapies, developing new products, and validating their
effectiveness, which collectively fuels market expansion. Collaborative
research initiatives involving industry players, academic institutions, and
veterinary professionals foster innovation and accelerate the development of
novel orthobiologic therapies. These partnerships enhance the research pipeline
and expedite the introduction of advanced treatments to the market.
Also, clinical trials and validation studies are
essential for demonstrating the safety and efficacy of orthobiologic
treatments. Positive outcomes from these studies support the adoption of new
therapies and provide evidence-based benefits to veterinarians and pet owners,
thereby driving market growth.
The growth of the global veterinary orthobiologics
market is propelled by a combination of factors. The increasing prevalence of
musculoskeletal disorders, advancements in regenerative medicine technology,
rising pet ownership and humanization trends, expansion of veterinary
practices, and substantial investments in research and development all
contribute to the market's expansion. These drivers collectively enhance the
adoption of orthobiologic therapies in veterinary medicine, reflecting a
dynamic and evolving sector poised for continued growth.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Veterinary Orthobiologics Market”
The Global Veterinary Orthobiologics Market is
segmented into product, animal, application, delivery mode, end user, regional
distribution, and company.
Based on delivery mode, the intra-articular
delivery segment has emerged as the predominant market leader, Intra-articular
delivery ensures that the therapeutic agents, such as platelet-rich plasma
(PRP) or stem cells, are administered directly to the site of injury or
degeneration. This direct application enhances the efficacy of the treatment by
focusing the therapeutic agents where they are needed most, leading to more
effective management of joint-related conditions. By delivering the
orthobiologic agents directly into the joint, the concentration of the
therapeutic substance at the target site is significantly higher compared to
systemic administration. This localized high concentration enhances the
treatment’s ability to promote healing, reduce inflammation, and alleviate pain
more effectively. Intra-articular delivery is particularly effective in
addressing symptoms associated with joint disorders, such as pain and
stiffness. By targeting the joint space, this method provides more immediate
and pronounced relief from symptoms, which contributes to its preference among
veterinarians and pet owners. Treatments administered via intra-articular
delivery can offer longer-lasting benefits compared to other delivery methods.
The direct application allows for a sustained therapeutic effect, as the agents
remain concentrated in the joint space for extended periods, promoting ongoing
joint health and functionality. One of the key advantages of intra-articular
delivery is the reduction in systemic exposure to therapeutic agents. By
delivering the treatment directly into the joint, the risk of systemic side
effects is minimized, making it a safer option for animals who may be sensitive
to systemic medications. The targeted nature of intra-articular delivery
ensures that the therapeutic agents act specifically on the joint, reducing the
likelihood of unintended effects on other parts of the body. This targeted
action enhances the overall safety profile of the treatment.
The Europe region is experiencing rapid market growth.
Europe boasts a well-established and sophisticated veterinary healthcare
infrastructure. The presence of numerous advanced veterinary clinics and
specialized centers, particularly those focusing on orthopedics and
regenerative medicine, supports the rapid adoption of innovative orthobiologic
treatments. These facilities are equipped with cutting-edge technology and have
a high level of expertise in managing complex musculoskeletal disorders. European
countries are known for their high standards of veterinary care and commitment
to animal welfare. This regulatory and practice environment fosters the
integration of advanced therapeutic options, such as orthobiologics, which are
increasingly sought after for their efficacy in treating a range of
musculoskeletal conditions.
There is a rising prevalence of musculoskeletal
disorders in both companion animals and livestock across Europe. This increase
in incidence drives demand for effective and innovative treatment options,
including orthobiologics, to address conditions such as arthritis, ligament
injuries, and degenerative joint diseases. The trend of pet humanization and
the growing number of pet owners in Europe contribute to increased expenditure
on veterinary care. Pet owners are increasingly seeking advanced treatments for
their animals, including orthobiologics, to ensure optimal health and quality
of life for their pets. Europe has a relatively supportive regulatory framework
for the approval and commercialization of veterinary products, including
orthobiologics. The European Medicines Agency (EMA) and national regulatory
bodies facilitate the approval process for new treatments, which accelerates
market entry and growth. The European Union’s efforts to harmonize standards
and regulations across member states streamline the introduction of innovative
veterinary products. This regulatory alignment helps companies navigate the
market more efficiently and ensures consistent product quality and safety
standards.
Major companies operating in Global Veterinary
Orthobiologics Market are:
- Zoetis Services LLC
- Boehringer Ingelheim International
GmbH
- Ardent Animal Health
- Enso Discoveries, LLC
- VetStem, Inc
- MEDREGO LLC
- Arthrex, Inc.
- Hilltop Biosciences
- Enovis Corporation
- Dechra Pharmaceuticals Limited
Download Free Sample Report
Customers can also request for 10% free customization
on this report
“Global Veterinary Orthobiologics market is poised for
significant growth, driven by a range of dynamic factors. The increasing
prevalence of musculoskeletal disorders, coupled with advancements in
regenerative medicine and rising pet ownership, creates a robust demand for
innovative orthobiologic treatments. The expansion of specialized veterinary
practices, supportive regulatory frameworks, and substantial investments in
research and development further fuel this growth. As technological innovations
continue to enhance treatment efficacy and accessibility, and as market players
increasingly focus on addressing the needs of both companion animals and
livestock, the veterinary orthobiologics sector is set to experience robust
expansion and evolving opportunities. This progress underscores a promising
future for the market, with ongoing developments poised to deliver advanced
therapeutic solutions and improve animal health outcomes worldwide.,” said Mr.
Karan Chechi, Research Director of TechSci Research, a research-based
management consulting firm.
“Veterinary Orthobiologics Market – Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Product (Stem Cells, Platelet-rich Plasma (PRP), Other), By Animal (Canine, Equine, Others), By Application (Osteoarthritis, Degenerative Joint Disease, Other), By Delivery Mode (Intra-muscular/Intra-lesional, Intra-articular, Others), By End User (Veterinary Hospitals, Veterinary Clinics, Others), By Region & Competition, 2019-2029F”, has evaluated the future growth potential of Global
Veterinary Orthobiologics Market and provides statistics & information on
market size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Global Veterinary
Orthobiologics Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com